Physician profile
Henry Blunk
NPI 1053932079
$5,498.37
in general payments reported to CMS, 2019-2025
28 companies · $2,578 in 2025
The $2,578 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.53 · 2022: $33.73 · 2023: $834 · 2024: $2,039 · 2025: $2,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,283 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,282.95 |
| Education | $168.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,282.41 | 2023-2025 | Tezspire, Airsupra, Fasenra |
| Novartis Pharmaceuticals Corporation | $830.73 | 2023-2025 | |
| Amgen INC. | $530.10 | 2022-2025 | Tezspire, Actimmune |
| Csl Behring | $465.46 | 2023-2025 | Hizentra, Haegarda, Andembry |
| Regeneron Healthcare Solutions, INC. | $386.83 | 2023-2025 | Dupixent |
| Genzyme Corporation | $367.36 | 2022-2025 | |
| Glaxosmithkline, LLC. | $269.44 | 2024-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $206.32 | 2023-2025 | Hyqvia, Takhzyro, Aralast |
| Genentech USA, INC. | $191.18 | 2023-2025 | Xolair |
| Octapharma USA, INC. | $168.67 | 2023-2025 | Octagam Immune Globulin (Human), Panzyga |
| Biocryst US Sales Co., LLC | $126.96 | 2024-2025 | Orladeyo |
| Ionis Pharmaceuticals, INC. | $80.26 | 2025 | Dawnzera |
| Pharming Healthcare, INC. | $76.05 | 2025 | Ruconest |
| Phadia US INC. | $68.70 | 2024-2025 | Immunocap |
| Grifols USA, LLC | $63.18 | 2024-2025 | Gamunex-C |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $60.34 | 2023-2024 | Auvi-Q |
| Pfizer INC. | $48.48 | 2024 | |
| Blueprint Medicines Corporation | $36.51 | 2023-2025 | Ayvakit |
| Horizon Therapeutics Plc | $31.22 | 2023 | Actimmune |
| Genentech, INC. | $31.00 | 2025 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.83 | 2021-2023 | Cyltezo |
| Baxter Healthcare | $27.16 | 2025 | Hillrom - Vest System Model 105 Home Care |
| X4 Pharmaceuticals, INC. | $26.23 | 2024 | Xolremdi |
| Azurity Pharmaceuticals, INC. | $25.43 | 2025 | Alvesco |
| Galderma Laboratories, L.P. | $19.00 | 2025 | Nemluvio |
| Lilly USA, LLC | $17.73 | 2025 | Ebglyss |
| Tersera Therapeutics LLC | $16.75 | 2025 | Quzyttir |
| Ars Pharmaceuticals Operations, INC. | $16.04 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Blunk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.